Results 141 to 150 of about 26,505 (287)
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10195-10209, November 2026.ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González +14 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10236-10247, November 2026.ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10664-10669, November 2026.ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen +39 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg +4 more
wiley +1 more source
Resistence of Euphorbia Heterophylla L. to ALS-inhibiting herbicides in soybean
Scientia Agricola, 2005 Herbicides are widely used in soybean for weed control, and the selection pressure attributed to the repeated use of herbicides with similar modes of action on the same site has caused selection for resistant biotypes within and among previously ...
Gerson Augusto Gelmini +3 more
doaj
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10603-10614, November 2026.ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires +10 more
wiley +1 more source
SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma
European Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu +6 more
wiley +1 more source
Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective
Immunology, Volume 179, Issue 3, Page 390-405, November 2026.Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac +7 more
wiley +1 more source